Medical Condition News

RSS

Study: Children with TBI more likely to experience daytime sleepiness, sleep disturbances

A new study suggests that children with traumatic brain injuries (TBI) have poorer sleep and more daytime sleepiness in comparison to healthy children.

9 Jun 2015

Scientists develop computational method to study link between birth month and disease risk

Columbia University scientists have developed a computational method to investigate the relationship between birth month and disease risk.

9 Jun 2015

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Quality control is important - this is not only applicable to industrial production but also true for all life processes. However, whereas an enterprise can start a large-scale recall in case of any doubt, defects in the quality control systems of cells are often fatal.

9 Jun 2015

Study shows autophagic defects are linked to sarcopenia

Sarcopenia is the aging-related loss of skeletal muscle mass and strength. Preventing sarcopenia is important for maintaining a high quality of life (QOL) in the aged population.

9 Jun 2015

Enhancing body's gut defense system can reverse bloodstream infections

An upset in the body's natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing a specific immune defense response, UT Southwestern Medical Center researchers have found.

9 Jun 2015

Findings could lead to new therapies that stop breast cancer progression

Scientists have discovered a trigger that allows breast cancer cells to spread to the lungs. They have found that blocking the signals in mice with breast cancer greatly reduces the number of secondary tumours found in the lungs.

9 Jun 2015

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).

9 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

8 Jun 2015

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).

8 Jun 2015

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced new data today demonstrating that use of its Non-Invasive Open Ventilation (NIOV) System in pulmonary rehabilitation was associated with significant improvement in mean exercise duration change (approximately 63 percent) among patients with chronic respiratory disease.

8 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.

8 Jun 2015

People now have powerful new option for relieving dry mouth symptoms

People who suffer from dry mouth, or xerostomia, now have a powerful new option for relieving their symptoms. Building on the success of its antioxidant oral care product line, Dallas-based PerioSciences LLC is launching Dry Mouth AO ProGel and a new MILD formula of its Hydrating AO ProRinse. The new products, along with the established Hydrating AO ProRinse and AO ProToothpaste, provide a complete Hydrating Oral Care System.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

New study gives insight into the mental health of teens, children with Down syndrome

A new study gives insight into the mental health of children and teens with Down syndrome and the behavioral medications that medical caregivers sometimes prescribe for them.

8 Jun 2015

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction.

8 Jun 2015

Medical Condition News

Study: Children with TBI more likely to experience daytime sleepiness, sleep disturbances

Scientists develop computational method to study link between birth month and disease risk

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Study shows autophagic defects are linked to sarcopenia

Enhancing body's gut defense system can reverse bloodstream infections

Findings could lead to new therapies that stop breast cancer progression

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Jazz enrolls first patients in JZP-110 Phase 3 study for treatment of EDS in patients with narcolepsy or OSA

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

People now have powerful new option for relieving dry mouth symptoms

New therapeutic target discovered for idiopathic pulmonary fibrosis

Global RA treatment market expected to increase just over $19 billion by 2020

New study gives insight into the mental health of teens, children with Down syndrome

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News